Clinical Trial

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-03-31; most recent amendment 2025-11-14.
Status change: Recruiting → Active, Not Recruiting 2025-11-14
Status change: Not Yet Recruiting → Recruiting 2023-06-27
Trial Details
NCT Number NCT05812027
Lead Sponsor TScan Therapeutics, Inc.
Conditions Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Enrollment 1,150 participants
Start Date 2023-06-26
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-01-14 (estimated)
Updated on ClinicalTrials.gov 2025-11-17